Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes.

Hwang, G S; Bhat, R; Crutchley, R D; Trivedi, M V

Hwang, G S; Bhat, R; Crutchley, R D; Trivedi, M V.

Afiliação

Hwang GS; Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA.
Bhat R; Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA.
Crutchley RD; Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA.
Trivedi MV; Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA.

Pharmacogenomics J ; 18(2): 201-208, 2018 04.

Article em En | MEDLINE | ID: mdl-28762370

Assuntos

Antineoplásicos Hormonais/sangue; Neoplasias da Mama/sangue; Neoplasias da Mama/genética; Citocromo P-450 CYP2D6/genética; Polimorfismo Genético/genética; Tamoxifeno/análogos & derivados; Animais; Antineoplásicos Hormonais/uso terapêutico; Neoplasias da Mama/tratamento farmacológico; Feminino; Humanos; Tamoxifeno/sangue; Tamoxifeno/uso terapêutico; Resultado do Tratamento

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Polimorfismo Genético / Tamoxifeno / Neoplasias da Mama / Antineoplásicos Hormonais / Citocromo P-450 CYP2D6 Tipo de estudo: Prognostic_studies / Systematic_reviews Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google